Therapeutic Doses of Eltrombopag do not Inhibit Hepatic BCRP in Healthy Volunteers: Intravenous Ceftriaxone as a Model

• Egile Nagusiak: Daniel Valente Neves (Egilea), Carolina Pinto Vieira (Egilea), Adriana Rocha (Egilea), Vera Lucia Lanchote (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2018-06-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

PURPOSE: Ceftriaxone elimination occurs through breast cancer resistance transporter (BCRP) and multidrug resistance-associated protein 2 (MRP-2) which are expressed on the canalicular membrane of hepatocytes. Eltrombopag, a thrombopoetin receptor agonist used in the treatment of immune thrombocytop...